Last reviewed · How we verify
BT-114143 Injection at High-dose
At a glance
| Generic name | BT-114143 Injection at High-dose |
|---|---|
| Sponsor | ScinnoHub Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluation of Safety, Efficacy, and Pharmacokinetics of BT-114143 Injection in Patients With Abnormal Uterine Bleeding (PHASE1)
- Study on BT-114143 Reducing Perioperative Bleeding in Total Knee Arthroplasty（TKA） (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BT-114143 Injection at High-dose CI brief — competitive landscape report
- BT-114143 Injection at High-dose updates RSS · CI watch RSS
- ScinnoHub Pharmaceutical Co., Ltd. portfolio CI